Depth of response may predict clinical outcome in patients with recurrent/metastatic head and neck cancer treated with pembrolizumab-containing regimens

BACKGROUND: Pembrolizumab-containing regimens are standards of care for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). The depth of response (DpR) predicts the survival of patients with several types of solid cancers; however, its association with the survival outcomes o...

Descripción completa

Detalles Bibliográficos
Autores principales: Saijo, Ken, Imai, Hiroo, Ouchi, Kota, Sasaki, Keiju, Yoshida, Yuya, Kawamura, Yoshifumi, Taniguchi, Sakura, Kasahara, Yuki, Komine, Keigo, Shirota, Hidekazu, Takahashi, Masanobu, Ishioka, Chikashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469278/
https://www.ncbi.nlm.nih.gov/pubmed/37664016
http://dx.doi.org/10.3389/fonc.2023.1230731

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469278/
https://www.ncbi.nlm.nih.gov/pubmed/37664016
http://dx.doi.org/10.3389/fonc.2023.1230731

Ejemplares similares